| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 1.5K | 5.2% | 7.2% |
| Total Income | 1.5K | 5.2% | 7.2% |
| Expenditure | 1.5K | 4.7% | 1.9% |
| PBT | 17.58 | 41.3% | 116.8% |
| Net Profit | 17.96 | 63.3% | 117.2% |
| OPM | 0.79% | 0.51pp | 9.10pp |
| NPM | 1.20% | 2.24pp | 8.68pp |
| EPS | 1.07 | 63.7% |
agilon health Reports Q2 2026 Results, Revenue Up 7% to $1.49 Billion, Raises Full-Year Guidance
06 Aug 2026 · 6 Aug, 1:46 am
Summary
agilon health announced strong second quarter 2026 results, with total revenues increasing 7% year-over-year to $1.49 billion. The company demonstrated significant financial improvements, with gross profit turning positive at $107 million and medical margin reaching $197 million, a substantial rebound from the prior year's losses. Adjusted EBITDA also saw a significant positive swing, reaching $70 million compared to a loss of $83 million in Q2 2025. These improved results have led agilon health to raise its full-year 2026 guidance for total revenues, medical margin, and Adjusted EBITDA, reflecting confidence in its strategic initiatives and Total Care Model.
Key Highlights
- 1
agilon health reported total revenues of $1.49 billion for the second quarter of 2026, an increase of 7% compared to $1.39 billion in the second quarter of 2025.
- 2
Gross profit improved significantly to $107 million in Q2 2026, a substantial increase from a gross loss of $52 million in Q2 2025.
- 3
Medical margin was $197 million in the second quarter of 2026, compared to a negative $53 million in the second quarter of 2025.
- 4
Adjusted EBITDA for the second quarter of 2026 was $70 million, a significant improvement from negative $83 million in the second quarter of 2025.
- 5
The company raised its full-year 2026 guidance for total revenues, medical margin, and Adjusted EBITDA.
- 6
Total members on the agilon platform decreased by 10% year-over-year to 549,000 as of June 30, 2026, reflecting a disciplined approach to contracting focused on profitability.
Management Comments
Tim O’Rourke
Our second quarter results exceeded our expectations, demonstrating meaningful progress across agilon's strategic initiatives and reinforcing our confidence in the strength of our Total Care Model. We are raising our full-year 2026 outlook which reflects stronger burden of illness execution, favorable medical cost trends, and continued operating discipline. As I have engaged with our physician partners, payors, and the agilon team, I am even more convinced about the strength and long-term growth potential of the agilon model and its positioning at the center of where value-based care is going.
Informational and educational content only. Not investment advice.